<?xml version="1.0" encoding="UTF-8"?>
<ref id="B134-pharmaceuticals-13-00096">
 <label>134.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Haschke</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Schuster</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Poglitsch</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Loibner</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Salzberg</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Bruggisser</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Penninger</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Krahenbuhl</surname>
    <given-names>S.</given-names>
   </name>
  </person-group>
  <article-title>Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects</article-title>
  <source>Clin. Pharmacokinet.</source>
  <year>2013</year>
  <volume>52</volume>
  <fpage>783</fpage>
  <lpage>792</lpage>
  <pub-id pub-id-type="doi">10.1007/s40262-013-0072-7</pub-id>
  <pub-id pub-id-type="pmid">23681967</pub-id>
 </element-citation>
</ref>
